ArticleFrontiers in public health2026
Cost-effectiveness analysis of first-line gefitinib plus anlotinib treatment for patients with stage IIIB-IV EGFR-mutated NSCLC in China.
Ping Chen et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.